«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 23

Page:

4489-4496

Research Field:

Publishing date:

Info

Title:

Study on pharmacokinetics differences of intravenous chemotherapy of cisplatin and intrapleural hyperthermic perfusion chemotherapy in internal medicine

Author(s):

SONG Jie; ZHANG Tao; LIAO Chenggong; HOU Yan; WANG Yun; LIU Lili

Department of Oncology,the Second Affiliated Hospital,the Air Force Medical University,Shaanxi Xi'an 710038,China.

Keywords:

HITHOC; HIPEC; IVC; casplatin; pharmacokinetics

PACS:

R730.5

DOI:

10.3969/j.issn.1672-4992.2024.23.011

Abstract:

Objective:To compare the pharmacokinetics and adverse reactions of cisplatin with hyperthermic intrathoracic chemotherapy (HITHOC),hyperthermic intraperitoneal chemotherapy (HIPEC) and intravenous chemotherapy (IVC).Methods:Select 60 patients diagnosed with malignant tumors by histopathology or cytology,who plan to receive cisplatin based IVC,HITHOC or HIPEC.The cisplatin dosage for all patients is 75 mg/m2,administered in three doses. The cisplatin dosage on the first day of treatment is 40 mg.This study only compared the pharmacokinetic parameters on the first day of treatment.At the beginning of treatment,2 mL of venous blood was collected from patients in the IVC group at 0.5,1,1.5,2,3,5,10,16,and 24 hours,while 2 mL of venous blood and perfusion fluid were collected from patients in the HITHOC and HIPEC groups at the aforementioned time points.Using HPLC method to determine the concentration of cisplatin in perfusion fluid and plasma,non compartment model analysis was performed on pharmacokinetic parameters using DAS2.0 software,and the concentration time curve of the drug was plotted.The AUC was calculated using linear trapezoidal rule from 0~24 hours,and the area under curve (AUC) of the three groups of patients was compared.According to the Common Adverse Reaction Terminology Evaluation Criteria (CTCAE 5.0),compare the differences in adverse reactions among three groups of patients.Results:The AUC0-24 h of cisplatin in the perfusion fluid was (64.32¡À27.12) ¦Ìg/(mL¡¤h) for the HITHOC group and (31.68¡À13.29) ¦Ìg/(mL¡¤h) for the HIPEC group,with a statistically significant difference(P<0.01).The AUC0-24 h of cisplatin in the plasma for the IVC,HITHOC,and HIPEC groups were (3.26¡À0.56) ¦Ìg/(mL¡¤h),(2.57¡À0.55) ¦Ìg/(mL¡¤h),and (3.02¡À0.52) ¦Ìg/(mL¡¤h),respectively,with a statistically significant difference(P<0.01).There was significant difference between IVC group and HITHOC group,but there was no significant difference between IVC group and HIPEC group.There was significant difference between HITHOC group and HIPEC group(P=0.01).There was no significant difference in the incidence of common adverse reactions among the three groups of patients(P£¾0.05).Conclusion:HITHOC can not achieve the systemic therapeutic effect of the same dose of cisplatin IVC,and HIPEC can achieve the systemic therapeutic effect of the same dose of cisplatin IVC.

References:

£Û1£ÝGAYEN S.Malignant pleural effusion:Presentation,diagnosis,and management£ÛJ£Ý.Am J Med,2022,135(10):1188-1192.
£Û2£ÝSPILIOTIS J,HALKIA E,DE BREE E.Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives£ÛJ£Ý.Current Oncology(Toronto,Ont),2016,23(3):e266-e275.
£Û3£ÝACS M,BABUCKE M,JUSUFI M,et al.Current clinical practices of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC)£ÛJ£Ý.Innov Surg Sci,2024,9(1):3-15.
£Û4£ÝREESE M,EICHELMANN AK,NOWACKI TM,et al.The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany£ÛJ£Ý.Langenbecks Arch Surg,2024,409(1):113.
£Û5£ÝAWAD A,AWAD M,ALAMI M,et al.Successful treatment of pseudomyxoma peritonei(PMP) through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(CRS-HIPEC):A case report and literature review£ÛJ£Ý.Int J Surg Case Rep,2024,119:109656.
£Û6£ÝFALLA-ZUNIGA LF,SARDI A,KING MC,et al.Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(CRS/HIPEC)£ÛJ£Ý.Pleura Peritoneum,2024,9(1):15-22.
£Û7£ÝLANGELLOTTI L,FIORILLO C,D'ANNIBALE G,et al.Efficacy of cytoreductive surgery(CRS)+HIPEC in gastric cancer with peritoneal metastasis:Systematic review and meta-analysis£ÛJ£Ý.Cancers(Basel),2024,16(10):1929.
£Û8£ÝLAVOUE V,OULDAMER L,HUCHON C.Correspondence on "Complications of HIPEC for ovarian cancer surgery:evaluation over two time periods" by Navarro Santana et al £ÛJ£Ý.Int J Gynecol Cancer,2024,34(6):965.
£Û9£ÝMOLDOVAN B,SAON CT,ADAM II,et al.Successful implementation of HITOC and HIPEC in the management of advanced ovarian carcinoma with pleural and peritoneal carcinomatosis£ÛJ£Ý.Diagnostics(Basel),2024,14(5):455.
£Û10£ÝSAQIB HWU,ABDULLAH A,MAJID A."Unveiling controversies:The role of HIPEC in colorectal cancer peritoneal metastasis"£ÛJ£Ý.Eur J Surg Oncol,2024,50(6):108345.
£Û11£ÝRIED M,EICHHORN M,WINTER H,et al.Expert recommendation for the implementation of hyperthermic intrathoracic chemotherapy(HITOC) in Germany£ÛJ£Ý.Zentralblatt Fur Chirurgie,2020,145(1):89-98.
£Û12£ÝLI Y,ZHOU YF,LIANG H,et al.Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies£ÛJ£Ý.World Journal of Gastroenterology,2016,22(30):6906-6916.
£Û13£ÝTURAGA K,LEVINE E,BARONE R,et al.Consensus guidelines from the American society of peritoneal surface malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy(HIPEC) in colorectal cancer patients in the United States£ÛJ£Ý.Annals of Surgical Oncology,2014,21(5):1501-1505.
£Û14£ÝATES O,AKSEL B,AKKUS MH,et al.HIPEC in ovarian cancer:When and to whom£ÛJ£Ý.Journal of the College of Physicians and Surgeons-Pakistan:JCPSP,2023,33(9):1001-1005.
£Û15£ÝSUN BJ,DANIEL SK,LEE B.The role of prophylactic and adjuvant hyperthermic intraperitoneal chemotherapy(HIPEC) in prevention of peritoneal metastases in advanced colorectal cancer£ÛJ£Ý.Journal of Clinical Medicine,2023,12(20):6443.
£Û16£ÝWONG EYT,TAN GHC,CHIA CSL,et al.Morbidity and mortality of elderly patients following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(HIPEC)£ÛJ£Ý.Asia-Pacific Journal of Clinical Oncology,2018,14(2):e193-e202.
£Û17£ÝTSUYOSHI H,INOUE D,KUROKAWA T,et al.Hyperthermic intraperitoneal chemotherapy(HIPEC) for gynecological cancer£ÛJ£Ý.The Journal of Obstetrics and Gynaecology Research,2020,46(9):1661-1671.
£Û18£ÝCHEN Z,ALI M,KAI Z,et al.HIPEC with CRS versus cytoreductive surgery(CRS) for the gastric cancer metastasis to peritoneum£ÛJ£Ý.Clinical & Translational Oncology:Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,2023,25(4):1011-1016.
£Û19£ÝLU C,LI L,LUO Z,et al.Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites£ÛJ£Ý.Neoplasma,2016,63(2):299-303.
£Û20£ÝCEELEN WP,VAN NIEUWENHOVE Y,VAN BELLE S,et al.Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer£ÛJ£Ý.Annals of Surgical Oncology,2012,19(7):2352-2359.
£Û21£ÝREICHMAN TW,CRACCHIOLO B,SAMA J,et al.Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma£ÛJ£Ý.Journal of Surgical Oncology,2005,90(2):51-58.
£Û22£ÝK¦ZNIGSRAINER I,HORVATH P,STRULLER F,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases:a single centre experience£ÛJ£Ý.Langenbeck's Archives of Surgery,2014,399(5):589-594.
£Û23£ÝPI¦BTEK S,SARNOWSKA E,KACPERCZYK-BARTNIK J,et al.Discrepancy between recommendations regarding hyperthermic intraperitoneal chemotherapy(HIPEC) in ovarian cancer management:a narrative review£ÛJ£Ý.Chin Clin Oncol,2024,13(3):37.
£Û24£ÝDELLA CORTE L,CONTE C,PALUMBO M,et al.Hyperthermic intraperitoneal chemotherapy(HIPEC):New approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis£ÛJ£Ý.Journal of Clinical Medicine,2023,12(22):7012.
£Û25£ÝDELLINGER TH.HIPEC in the consolidation setting:A consolation prize for chemorefractory ovarian cancer£ÛJ£Ý.Annals of Surgical Oncology,2023,30(6):3177-3179.
£Û26£ÝMARGIOULA-SIARKOU C,ALMPERIS A,PAPANIKOLAOU A,et al.HIPEC for gynaecological malignancies:A last update(Review)£ÛJ£Ý.Medicine International,2023,3(3):25.
£Û27£ÝCOTTE E,COLOMBAN O,GUITTON J,et al.Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure£ÛJ£Ý.Journal of Clinical Pharmacology,2011,51(1):9-18.
£Û28£ÝANSALONI L,COCCOLINI F,MOROSI L,et al.Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer£ÛJ£Ý.British Journal of Cancer,2015,112(2):306-312.
£Û29£ÝZIVANOVIC O,ABRAMIAN A,KULLMANN M,et al.HIPEC ROC I:a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer£ÛJ£Ý.International Journal of Cancer,2015,136(3):699-708.
£Û30£ÝAMBROGI MC,KORASIDIS S,LUCCHI M,et al.Pleural recurrence of thymoma:surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy£ÛJ£Ý.European Journal of Cardio-thoracic Surgery,2016,49(1):321-326.
£Û31£ÝVAN DRIEL WJ,KOOLE SN,SIKORSKA K,et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer£ÛJ£Ý.N Engl J Med,2018,378(3):230-240.
£Û32£ÝLIU L,ZHANG N,MIN J,et al.Retrospective analysis on the safety of 5 759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy(HIPEC)£ÛJ£Ý.Oncotarget,2016,7(16):21570-21578.
£Û33£ÝLIU L,SUN L,ZHANG N,et al.A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-¢ó gastric cancer£ÛJ£Ý.International Journal of Hyperthermia,2022,39(1):239-245.
£Û34£ÝLIU L,ZHANG T,SONG X,et al.Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion:a multi-center randomized clinical trial£ÛJ£Ý.International Journal of Hyperthermia,North American Hyperthermia Group,2023,40(1):2241689.

Memo

Memo:

National Natural Science Foundation of China£¨No.81372608£©;¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð×ÊÖúÏîÄ¿(±àºÅ£º81372608)

Common functions

Last Update: 2024-11-01